Reported Saturday, Merck’s Remigromig Delivers Mean BCVA Gains Of 9.1 Letters At 0.5 Mg And 8.7 Letters At 0.8 Mg Versus 11.8 For Ranibizumab, Meeting Non-Inferiority, With No Secondary Endpoint Showing Superiority

뉴스 본문을 불러오고 있어요.

Reported Saturday, Merck’s Remigromig Delivers Mean BCVA Gains Of 9.1 Letters At 0.5 Mg And 8.7 Letters At 0.8 Mg Versus 11.8 For Ranibizumab, Meeting Non-Inferiority, With No Secondary Endpoint Showing Superiority | 웨이프 WAPE

Reported Saturday, Merck’s Remigromig Delivers Mean BCVA Gains Of 9.1 Letters At 0.5 Mg And 8.7 Letters At 0.8 Mg Versus 11.8 For Ranibizumab, Meeting Non-Inferiority, With No Secondary Endpoint Showing Superiority

기사 요약

관련 종목

댓글 —